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Aim
• Evaluate the safety and tolerability of intra-tumoral LTX-315  in monotherapy 
or in combination with either ipilimumab or pembrolizumab  in patients with 
transdermally accessible tumors
• Determine the recommended phase II dose and schedule
LTX-315 is a first in class oncolytic peptide 
with unique “release and reshape” MoA
CONFIDENTIAL
LTX-315 is a fir t in class oncolytic peptide with 
unique «release and reshape» MoA1-9
Preclincial studies of LTX-315 demonstrates complete regression of injected and non-
injected tumors (i.e. Abscopal effect)
Immune related response (irRC) assessment
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LTX-315 converts cold tumors to hot
Treatment
No. of patients 
treated
No. of patients with biopsies 
evaluable for CD8 IHC to date
No. of patients with increased 
CD8+ T cells in post treatment tumors
LTX-315 28 17 15 (88%)
LTX-315 + Pembrolizumab 9 5 4 (80%)
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Treatment # patients
treated
# patients with biopsies
evaluable for CD8 IHC  to 
date
# patients with increased
CD8+ T cells in post 
treatment tumors
LTX-315 28 17 15 (88%)
LTX-315 + Pembrolizumab 6 3 3 (100%)
Increase in CD8 gene expression in tumors upon LTX-315 treatment




























Melanoma Breast cancerDesmoid tumorEpidermoid 
cancer
MelanomaLeiomyo-sarcoma
Increase in CD8 gene expression in tumors upon LTX-315 treatment
Hierarchical Clustering of Immunosign® 21 Immune Gene Signature (HalioDx) 
which profiles expressions of a pre-defined set of effector T cell, Th1, chemokine, 
and cytokine genes.
Gene expression in tumor pre and post treatment




• Safety (including DLTs, AEs, SAEs, lab assessments) of LTX-315
Secondary Endpoints
• LTX-315 related Immune parameters in tumor and peripheral blood 
• Anti-tumor activity of LTX-315 by CT scan assessment (immune-related 
response criteria (irRC))
*AEs occuring in ≥ 2 patients per CTC Version 4.0
# No grade 4 LTX-315 related AEs reported 
¥ Reported as both LTX-315 and Pembrolizumab related
Patient population
• Advanced/metastatic disease (all tumor types)  
• At least one transdermally accessible lesion of ≤ 10 cm in diameter
LTX-315 Monotherapy  
(N=36)*
LTX-315 related  
adverse event
Grade 1-2 
(No. of pt (%))
Grade 3-4# 
(No. of pt (%))
Hypotension 10 (28%) -
Parasthesia 8 (22%) -
Rash 10 (28%) -
Flushing 8 (22%) -
Pruritis 4 (11%) -
Tumor pain 2 (6%) 2 (6%)
Allergic reaction 1(3%) 4 (14%)
Pain (injection site) 2 (6%) 2 (7%)
LTX-315 Combination therapy  
(Ipilimumab/pembrolizumab) (N=15)
LTX-315 related  
adverse event
Grade 1-2 
(No. of pt (%))
Grade 3-4# 
(No. of pt (%))
Allergic reaction 4 (29%) 1 (7%)
Pain (injection site) 3 (20%) 1 (7%)
Tumor pain 2 (13%) -
Fatigue 2 (13%) -
Pneumonitis¥ - 1 (7%)
LTX-315 Monotherapy
LTX-315 dose per injection No. of patients Tumor type 
Single/sequential lesion injection
2-7mg (1-2 injections per lesion) 23 Melanoma (7); Breast (6); Sarcoma (3); H&N (3); Adrenal (1); Urethral (1); 
Desmoid (1); Pancreas
 Multiple (≥ 1) lesion injection
3mg (1-8 injections per lesion) 8 Head & Neck; Breast; Vaginal SCC; melanoma; sarcoma (2); Anal Ca; Desmoid 
4mg (1-6 injections per lesion) 5 Head & Neck (2);Anal Ca; Sacroma; Gastric ca
LTX-315 + Ipilimumab 
Metastatic melanoma  
(post-PD1/L1 treatment; multiple (≥ 1) lesion injection)
LTX-315 dose per injection No. of patients
3mg (1-4 injections per lesion) 4
LTX-315 + Pembrolizumab
Metastatic Triple Negative Breast Cancer (2-5th line);  
multiple (≥ 1) lesion injection)
LTX-315 dose per injection No. of patients
3mg (1-2 injections per lesion) 4














































































































































LTX-315 generates a systemic tumor 
specific immune response
Case study: patient 471-016, Breast cancer, Monotherapy
Tumor pre treatment• 128 T cell clones expanded 
in blood post treatment.
• Clones expanding in 
blood were predominantly 


























Contracted in blood  
& present in tumor
Expanded in blood
Expanded in blood  
& present in tumor
No significant change 
in frequency
Not significant & in tumor
1
▪ 128 T cell clones expanded 
in blood post treatment.
Contracted in blood
Contracted in blood & present in tumor
Expanded in blood
Expanded in blood & present in tumor
No significant change in frequency
Not significa t & i  tumor
LTX-315 generate a systemic tumor specific immune response
Case study: patient 471-016, Breast cancer, Monotherapy
▪ Clones expanding in blood 
were predominantly present 
in treated tumor.
T CELL CLONES IN BLOOD PRE TREATMENT
TUMOR PRE TREATMENT TUMOR POST TREATMENT 







































▪ 128 T cell clones expanded 
in blood post treatment.
Contracted in blood
Contracte  in blood & present in tumor
Expanded in blood
Expanded in blood & present in tumor
No significant change in frequency
Not significant & in tumor
▪ Clones expanding in blood 
were predominantly present 
in treated tumor.




























































T cell clones expanded in blood are 
detected in post-treated tumors
• Clones expanding in blood are 
detected in post-treatment 
tumor biopsies; median 49%, 6 
patients analyzed.
• In contrast, the expansion of 
pre-treatment-tumor associated 
clones is less in all but one patient; 
median 23%. 
• Contracted clones in blood were 
not detected in the tumor in 2 of 
the 6 patients. 







Melanoma (Mono and Combo)
Breast (Mono and Combo)
Sarcoma (Mono)
























T cell clones expanded in blood are detected in post-treated tumors
1
▪ Approximately 49% (median) of clones 
expanding in blood are detected in post-
treatment tumor biopsies (6 patients 
analyzed).
▪ In contrast, the expansion of pre-
treatment-tumor associated clones is 
less in all but one patient (median 23%).
▪ Contracted clones in blood were not 









• LTX-315 converts “cold” tumors to “hot”, as evidences by increase of tumor 
infiltrating lymphocytes (CD8+ T cells) and gene expression analysis.
• TCR clonality analysis of blood and tumors samples show that LTX-315 
generates a systemic anti-tumor T cell response. 
• LTX-315 is generally safe and tolerable. No MTD has been reached.
• Stable disease (SD) by irRC observed with LTX-315 mono therapy (8/15 pts)
• Durable SD by irRC observed (1/4 pts) with LTX-315 + ipilimumab (32 wks, 
ongoing)
• Partial Remission (PR) by irRC observed (1/8 pts) with LTX-315 + pembrolizumab 
(10 wks, ongoing)
• Results support the rationale and potential benefit of LTX-315 as a novel 
intratumoral immunotherapy; A phase II multi-arm combination trial is planned 
in 2018
